Related Experiment Video
Updated: Dec 19, 2025
Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
Published on: October 15, 2019
Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis
Jordan Brown1, Blair Quattrochi1, Colleen Everett1
1Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
Abstract:
Intestinal microbiota alterations have been found to be directly related to a wide range of disease states in humans, including multiple sclerosis (MS). The etiology of MS is highly debated and subsequently, there is no cure. Research dedicated to MS and its murine model, experimental autoimmune encephalomyelitis (EAE), have found that dysbiosis of the gut microbiota may play a role in the disease state and severity. In this review, we discuss the characteristic dysbiosis in MS, the role commensal-derived ligands may have in the pathogenesis of the disease, and the possibility of targeting the microbiota as a future therapy.
Insights
Gut microbiota dysbiosis is linked to multiple sclerosis (MS) and its animal model, EAE. Targeting gut bacteria may offer a future therapeutic strategy for MS.
Area of Science:
- Neuroimmunology
- Microbiome Research
- Gastroenterology
Background:
- Intestinal microbiota alterations are associated with various human diseases, including multiple sclerosis (MS).
- The exact causes of MS remain unclear, and no definitive cure currently exists.
- Gut dysbiosis, an imbalance in the gut microbiota, is implicated in the development and severity of MS and its animal model, experimental autoimmune encephalomyelitis (EAE).
Purpose of the Study:
- To review the characteristic gut microbiota dysbiosis observed in multiple sclerosis patients.
- To explore the potential role of microbial-derived ligands in the pathogenesis of MS.
- To discuss the therapeutic potential of targeting the gut microbiota for MS treatment.
Main Methods:
- Literature review of studies investigating the gut microbiota in multiple sclerosis and EAE.
- Analysis of research on the immunological impact of commensal microbiota.
- Synthesis of findings related to microbiota-targeted therapies.
Main Results:
- Characteristic patterns of gut dysbiosis are consistently observed in individuals with MS.
- Commensal microbiota ligands may influence the immune responses contributing to MS pathogenesis.
- Modulating the gut microbiota presents a promising avenue for future MS therapies.
Conclusions:
- Gut microbiota dysbiosis is a significant factor associated with multiple sclerosis.
- Understanding the interplay between the gut microbiota and the immune system is crucial for MS research.
- Targeting the intestinal microbiota holds potential as a novel therapeutic strategy for managing multiple sclerosis.
More Related Videos
08:24Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
08:17Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...